Carrier Screening is a Deficient Strategy for Determining Sperm Donor Eligibility and Reducing Risk of Disease in Recipient Children
Open Access
- 22 April 2016
- journal article
- research article
- Published by SAGE Publications in Genetic Testing and Molecular Biomarkers
- Vol. 20 (6) , 276-284
Abstract
Aims: DNA-based carrier screening is a standard component of donor eligibility protocols practiced by U.S. sperm banks. Applicants who test positive for carrying a recessive disease mutation are typically disqualified. The aim of our study was to examine the utility of a range of screening panels adopted by the industry and the effectiveness of the screening paradigm in reducing a future child's risk of inheriting disease. Methods: A cohort of 27 donor applicants, who tested negative on an initial cystic fibrosis carrier test, was further screened with three expanded commercial carrier testing panels. These results were then compared to a systematic analysis of the applicants' DNA using next-generation sequencing (NGS) data. Results: The carrier panels detected serious pediatric disease mutations in one, four, or six donor applicants. Because each panel screens distinct regions of the genome, no single donor was uniformly identified as carrier positive by all three panels. In contrast, systematic NGS analysis identified all donors as carriers of one or more mutations associated with severe monogenic pediatric disease. These included 30 variants classified as “pathogenic” based on clinical observation and 66 with a high likelihood of causing gene dysfunction. Conclusion: Despite tremendous advances in variant identification, understanding, and analysis, the vast majority of disease-causing mutation combinations remain undetected by commercial carrier screening panels, which cover a narrow, and often distinct, subset of genes and mutations. The biological reality is that all donors and recipients carry serious recessive disease mutations. This challenges the utility of any screening protocol that anchors donor eligibility to carrier status. A more effective approach to reducing recessive disease risk would consider joint comprehensive analysis of both donor and recipient disease mutations. This type of high-resolution recessive disease risk analysis is now available and affordable, but industry practice must be modified to incorporate its use.Keywords
This publication has 41 references indexed in Scilit:
- Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited diseaseHuman Genetics, 2013
- An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individualsGenetics in Medicine, 2013
- Deleterious- and Disease-Allele Prevalence in Healthy Individuals: Insights from Current Predictions, Mutation Databases, and Population-Scale ResequencingThe American Journal of Human Genetics, 2012
- Predicting the Functional Effect of Amino Acid Substitutions and IndelsPLOS ONE, 2012
- Comprehensive Carrier Screening and Molecular Diagnostic Testing for Recessive Childhood DiseasesPLoS Currents, 2012
- Integrative Genomics Viewer (IGV): high-performance genomics data visualization and explorationBriefings in Bioinformatics, 2012
- Optimal DNA tier for the IRT/DNA algorithm determined by CFTR mutation results over 14years of newborn screeningJournal of Cystic Fibrosis, 2011
- α-thalassaemiaOrphanet Journal of Rare Diseases, 2010
- A method and server for predicting damaging missense mutationsNature Methods, 2010
- Fast and accurate long-read alignment with Burrows–Wheeler transformBioinformatics, 2010